New bladder cancer drug tested before surgery – early safety check
NCT ID NCT05055050
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 32 times
Summary
This early-phase study tested the safety of a drug called UGN-201 in 10 people with bladder cancer who were scheduled to have their bladder removed (cystectomy). The main goal was to see if the drug caused any serious side effects before or after surgery. Researchers also looked at whether the drug helped shrink tumors and checked for changes in the immune system and other markers in blood, urine, and tumor tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.